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In the current issue “Asthma: Novel developments from bench
to bedside” a number of key topics relevant for asthma devel-
opment reaching from epidemiology and lung function to the
role of early immune regulation, genetics, and epigenetics as
well as external factors such as viruses and the microbiome
summarize recent knowledge paired with future perspectives
for the next decade of asthma research and clinical translation.
Insight into local airway immune responses translating from
mice to men and the role of omics for asthma sum up the
complex nature of this multifactorial disease. Several asthma
phenotypes in combination with underlying endotypes are
tackled in a number of the subsequent articles.
Asthma indeed represents a clinical syndrome affecting all
age groups [1]. Asthma prevalence worldwide has rapidly
increased in the last few decades. Although asthma prevalence
has recently plateaued and even decreased in some areas of the
world, continuing increase in other areas has been seen. Many
risk factors and their distinct distribution in different areas of
the world may explain the differences in prevalence, which
will be discussed in “Asthma epidemiology and risk factors”
in this issue [1]. In the article “Lung functional development
and asthma trajectories” it is illustrated that a possible mech-
anism for a sustained effect of impaired lung function on asth-
ma is the influence of early life risk factors on early life lung
functional growth and development, representing the most
susceptible phase of lung growth and plasticity. Hereditary
and environmental peri- and postnatal factors on lung func-
tional development are summarized including air pollution,
tobacco exposure, nutrition, intrauterine growth retardation,
prematurity, early life infections, microbiome, and allergies
and their effect on lung functional trajectories [2]. While for
example prematurity impairs lung growth directly, the influ-
ence of a number of environmental factors is mediated
through inflammatory processes such as infections or oxida-
tive stress. Timing and nature of these influences lead to de-
grees of impaired lung functional capacity in early adulthood
[2]. Future long-term respiratory morbidity such as chronic
asthma or chronic obstructive airway disease (COPD) is
discussed as well as possibilities to prevent or modify early
abnormal lung functional growth trajectories.
In parallel with lung development, it is critical how the im-
mune system of a child responds to the interaction of genetic,
epigenetic, and environmental factors andwhether effective strat-
egies for a balanced and healthy immune maturation can be
assured to prevent asthma development [3]. Several phases of
susceptibility in a child’s life are important. Pregnancy and early
childhood are particularly susceptible for exogenous influences
based on the developing nature of a child’s immune system.
Endogenous influences such as family history and genetics are
immutable, and epigenetic regulations can be modulated by both
heredity and environmental exposures. Prenatal influences in-
cluding mother’s nutrition, smoking, or infections influence the
interplay of innate and adaptive immune regulation and peri- and
postnatal influences including mode of delivery. Induction and
continuous training of healthy maturation early in life comprise
balanced innate immunity and an equilibrium of T cell subpop-
ulations to counter-regulate pro-inflammatory or exuberant im-
mune reactions. In later childhood, compensatory immunemech-
anisms are required to modulate deviant regulation of a child’s
already primed immune trajectory [3]. The specific effects of
exogenous and endogenous influences on a child’s maturing
immune system are summarized in “Role of early life immune
regulation in asthma development,” and it’s importance and po-
tential intervention for early prevention and treatment strategies
are delineated.
In addition to early life immune regulation, in “Recent
findings in the genetics and epigenetics of asthma and
This article is a contribution to the special issue on Asthma: Novel
developments from bench to bedside - Guest Editor: Bianca Schaub
* Bianca Schaub
bianca.schaub@med.uni-muenchen.de
1 University Children’s Hospital Munich, LMU Munich,
Lindwurmstr.4, 80337 Munich, Germany
2 German Lung Centre, CPC-M, Munich, Germany
Seminars in Immunopathology (2020) 42:1–3
https://doi.org/10.1007/s00281-020-00786-0
allergy,” recent developments of a few key topics in this field
are summarized. Several studies have focused on overlapping
or specific phenotypes within the allergy spectrum and be-
yond, looking for common genetic traits shared between dif-
ferent diseases or disease entities. Importantly, asthma and
allergy genetics in populations genetically different from
European ancestry have been addressed, being key as the ma-
jority of new asthma patients are not white [4]. In epigenetics,
several large-scale epigenome-wide association studies
(EWAS) have been performed and interaction between envi-
ronment and epigenetic signatures were of focus. Finally, the
field of pharmacogenetics has been shown central to under-
stand the susceptibility for and mechanisms of current asthma
and allergy therapies, while in parallel, scientific answers to
the availability of novel drugs promising individualized ther-
apy are urgently needed [4].
While genetics and epigenetics are relevant for asthma de-
velopment without doubt, respiratory viral infections are
known as key triggers of asthma exacerbations. The common
cold virus rhinovirus (RV) is the most prevalent pathogen
circulating in the community with high diversity with approx-
imately 170 genotypes, an effective replication in T helper 2
cell biased, inflammatory milieu, and specific risk genes.
Decreased interferon responses, disrupted airway epithelial
barrier, environmental exposures, and nutritional deficiencies
increase the risk to RV and other virus infections [5]. The
debate whether viruses are the hen (causative) or the egg in
asthma development is ongoing. Time wise, respiratory syn-
cytial virus (RSV) is the leading causative agent of bronchi-
olitis in the first year of life, whereas RV starts to dominate
from the second year on. Breathing problems induced by ei-
ther of these viruses is associated with subsequent asthma,
with higher risk for children with severe RV-induced wheez-
ing. RV mostly represents a risk factor for later atopic asthma,
and RSVis more likely associated with subsequent non-atopic
asthma. Treatments inhibiting inflammation (e.g., corticoste-
roids or anti-IgE) effectively decrease RV-induced wheezing
and asthma exacerbations. The anti-RSV monoclonal anti-
body, palivizumab, decreases the risk of severe RSV illness
and subsequent recurrent wheeze [5]. In “Role of viruses in
asthma,” a better understanding of personal and environmen-
tal risk factors and inflammatory mechanisms leading to asth-
ma is discussed central for developing new strategies for the
prevention and treatment of asthma.
In the timely topic “Dysbiosis of the gut and lung
microbiome has a role in asthma,” the authors describe how
the development of asthma is influenced by environmental
and exogenous factors synergizing with genetic predisposi-
tion, shaping the lung microbiome in particular during peri-
and postnatal phases. A healthy lung microbiome is charac-
terized by bacteria belonging to the phyla Bacteroidetes,
Actinobacteria, and Firmicutes [6]. As one example for mod-
ulation, viral respiratory infections are associated with
increased proteobacteria with genera Haemophilus and
Moraxella in young children and adult asthmatics. This
dysbiosis supports induction of inflammatory pathways con-
tributing to bronchoconstriction and bronchial hyper respon-
siveness. Exogenous factors can influence the natural lung
microbiota composition in a positive manner such as in farm-
ing environments or negatively such as allergens or air pollut-
ants do. Gut microbiota dysbiosis also influences asthma path-
ogenesis. Antibiotics, antiulcer medications, and other drugs
severely impair gut and lung microbiota. Resulting dysbiosis
and reduced microbial diversity dysregulate the bidirectional
crosstalk across the gut-lung axis, resulting in hypersensitivity
and hyper reactivity to respiratory and food allergens. Efforts
are undertaken to reconstitute the microbiota and immune
balance by probiotics and engineered bacteria, but results
from human studies do not yet support their efficacy in asthma
prevention or treatment [6]. In summary, dysbiosis of gut and
lung seem to be critical causes to the increased emergence of
asthma.
In the article “Modulating local airway immune re-
sponses to treat allergic asthma: lessons from experimen-
tal models and human studies,” the current understanding
of the contribution of local innate immune elements in the
development and maintenance of inflammatory airway re-
sponses in mice and men is comprehensively summarized,
and available leads for successful targeting of those path-
ways for future therapeutics are envisioned. Allergic asth-
ma with Th2-type immunity represents 90% of child and
50% of adult asthma cases. Research on animal models of
allergic disease has led to the generation of biologicals, a
novel class of drugs, targeting components of Th2-type
inflammation [7]. Although highly efficient in subclasses
of patients, only symptomatic stages of diseases are
targeted, and recently, it is suggested to rather focus on
earlier stages in the inflammatory cascade as underlying
cause of allergic airway inflammation. Thus, a focus on
changing and redirecting the initiation of type 2 inflamma-
tory responses against allergens and certain viral agents for
example via innate immunity as driver of Th2-type immu-
nity may be of longer-lasting, disease-modifying effects, if
not even at some point cure for asthma [7].
Finally, “Omics for the future in asthma” focuses on refin-
ing of asthma phenotypes and understanding their underlying
biological structure in order to facilitate precision medicine
approaches. The use of a number of omics methods such as
(epi)genomics, transcriptomics, proteomics, metabolomics,
microbiomics, and exposomics are relevant to investigate
asthma from diverse angles [8]. Although technological ad-
vancement led to increased application of omics studies in the
asthma field, several design and methodological challenges
still need to be tackled before omics can be truly translated
to asthma patient care. Collaborations in centralized harmo-
nized work frame such as consortia with consistent
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methodologies will support worldwide research teams to tack-
le these challenges. Challenges such as the lack of standardi-
zation of sampling and analytical methodologies and valida-
tion of findings need to be tackled for personalized patient
care [8]. The authors envision an encouraging future of omics
in asthma with a number of challenges for translation to pa-
tient care, which are reviewed.
Finally, this bouquet of further developing and novel fields
of asthma research will only in concert be able to bring this
complex field of this multifactorial disease forward. Thus,
combined efforts across studies, country borders, and ethnic-
ities are urgently needed. By harmonizing already available
and designing novel well-defined cohorts together with clini-
cally well-characterized phenotyping of the asthma syndrome,
large, open consortia, well-prepared to integrate novel strate-
gies of basic, clinical, and analysis methods, can offer answers
to the currently unmet need, namely to understand distinct
mechanisms of asthma endotypes and to treat the majority of
asthma patients more individually and more efficiently.
Finally, for asthma prevention, murine and human immuno-
logical studies in concert with genetic and epigenetic expertise
are crucial to disentangle the key mechanisms for effective
prevention strategies, early in life, but possibly also in child-
hood, later adolescence, and adulthood.
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